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BACKGROUND. Androgens play a crucial role in prostate cancer, hence the androgenic
pathway has become an important target of therapeutic intervention. Previously we discov-
ered that gene fusions between the 50-untranslated region of androgen regulated gene
TMPRSS2 and the ETS transcription factor family members were present in a majority of
the prostate cancer cases. The resulting aberrant overexpression of ETS genes drives tumor
progression.
METHODS. Here, we evaluated the expression levels of 5a-reductase isoenzymes in pros-
tate cancer cell lines and tissues. We tested the effect of dutasteride, a 5a-reductase inhibitor,
in TMPRSS2–ERG fusion-positive VCaP cell proliferation and cell invasion. We also evaluat-
ed the effect of dutasteride on the TMPRSS2–ERG fusion gene expression. Finally, we tested
dutasteride alone or in combination with an anti-androgen in VCaP cell xenografts tumor
model.
RESULTS. Our data showed that 5a-reductase SRD5A1 and SRD5A3 isoenzymes that are
responsible for the conversion of testosterone to DHT, are highly expressed in metastatic
prostate cancer compared to benign and localized prostate cancer. Dutasteride treatment
attenuated VCaP cell proliferation and invasion. VCaP cells pre-treated with dutasteride
showed a reduction in ERG and PSA expression. In vivo studies demonstrated that dutaster-
ide in combination with the anti-androgen bicalutamide significantly decreased tumor bur-
den in VCaP cell xenograft model.
CONCLUSIONS. Our findings suggest that dutasteride can inhibit ERG fusion-positive
cell growth and in combination with anti-androgen, significantly reduce the tumor burden.
Our study suggests that anti-androgens used in combination with dutasteride could syner-
gistically augment the therapeutic efficacy in the treatment of ETS-positive prostate cancer.
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INTRODUCTION
A majority of prostate cancer patients harbor gene
fusions involving androgen regulated promoters and
members of the ETS family of transcription factors
[1–3] that are known to play a critical role in prostate
tumorigenesis. Overexpression of ERG in primary or
immortalized benign prostate epithelial cells induces
an invasion-associated transcriptional program [4].
Conversely, ERG knockdown in VCaP cells, an andro-
gen-sensitive metastatic prostate cancer cell line har-
boring the TMPRSS2–ERG gene fusion, decreases cell
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proliferation and tumor growth in mice [5]. Other
studies demonstrated that VCaP cells and immortal-
ized benign prostate epithelial cells (RWPE-1) overex-
pressing ERG directly engage components of the
plasminogen activation pathway to mediate cellular
invasion, potentially representing a downstream ERG
target susceptible to therapeutic intervention [4]. Fur-
thermore, transgenic mice expressing the ERG gene
fusion product under androgen regulation develop
mouse prostatic intraepithelial neoplasia (mPIN), a
precursor lesion of prostate cancer [4,6,7], and when
combined with other relevant genomic lesions such as
loss of PTEN, result in the development of invasive
carcinoma [7]. Recently, we showed that ERG binds
to androgen receptor (AR) and disrupts the regulation
of a majority of its target genes. In addition, ERG acti-
vates the polycomb protein, EZH2, facilitating a stem-
cell-like dedifferentiation program, suggesting that
TMPRSS2–ERG plays a key role in cancer by abrogat-
ing lineage-specific differentiation of the prostate [8].
Androgen-AR axis plays a critical role in prostate
tumorigenesis, thus inhibition of AR activity has been
a major therapeutic strategy for prostate cancer treat-
ment. Anti-androgens that block AR function include
bicalutamide (Casodex), flutamide, nilutamide, and
the steroidal anti-androgen cyproterone acetate [9].
Another potent AR inhibitor, apregnenolone-derived
compound abiraterone, renders both potency and se-
lectivity in CYP17 inhibition and has demonstrated
efficacy in reducing the weights of androgen-depen-
dent organs, such as prostate, seminal vesicles, and
testes [10]. Although responding initially to androgen
deprivation therapy by depletion of gonadal testoster-
one (T), metastatic tumors almost invariably develop
into castration-resistant prostate cancer (CRPC). AR
amplification, gain-of-function mutations, and novel
splice variant expression are thought to be responsi-
ble for this resistance [11]. The development of CRPC
is also dependent upon the intratumoral generation of
the potent androgen, dihydrotestosterone (DHT). As
part of the androgen axis, the enzyme 5a-reductase is
responsible for the conversion of circulating T into
DHT [12,13] and in CRPC, adrenal androgens are con-
verted to DHT by these enzymes. Three 5a-reductase
isoforms, SRD5A1, SRD5A2, and SRD5A3 have been
characterized in the prostate [14]. In CRPC, SRD5A1
is overexpressed and a recent study indicated that
SRD5A1 bypasses T and instead uses androstenedi-
one as a substrate for 5a-reduction to produce 5a-
androstanedione, which is then converted to DHT
[15]. Inhibitors of 5a-reductases block the conversion
of T to the more potent androgen, DHT resulting
in reduced androgenic activity in the prostate.
5a-Reductase inhibitors such as finasteride and dutas-
teride are commonly used in cases of prostatic
hyperplasia [16]. Recent report from a clinical trial
suggested that dutasteride could prove beneficial for
low-risk prostate cancer patients [17]. Furthermore,
patients successfully treated with high doses of dutas-
teride were predominantly negative for TMPRSS2–
ERG genetic rearrangement [18].
Since androgen induces the expression of
TMPRSS2–ERG, in the present study we investigated
the effect of dutasteride on the expression of ERG as
well as cellular phenotypes of the TMPRSS2–ERG
rearrangement-positive prostate cancer cell line, VCaP.
Results from our study suggest that dual 5a-reductase
inhibitor, dutasteride, inhibits the expression of
TMPRSS2–ERG in vitro under androgen-deprived
condition. We also demonstrate that dutasteride, in
combination with bicalutamide, leads to greater re-
duction in VCaP tumor burden than either inhibitor
alone. Thus, our study provides pre-clinical evidence
for a potential therapeutic strategy for the treatment
of ETS fusion-positive prostate cancer.
MATERIALSANDMETHODS
Cell Lines,TissueSamples,
andDutasterideTreatments
The VCaP prostate cancer cell line was derived
from a vertebral metastasis of a patient with castra-
tion resistant metastatic prostate cancer and was
kindly provided by Kenneth Pienta (University of
Michigan). VCaP cells were cultured in DMEM Gluta-
max medium supplemented with 10% fetal bovine se-
rum (FBS; Invitrogen, Carlsbad, CA). LNCaP cells
were purchased from the American Type Cell Culture
(ATCC, used at passage number 30–40) and cultured
in RPMI-1640 medium supplemented with 10% FBS.
Both cell lines were maintained in a 5% CO2, 95% air-
humidified atmosphere at 378C. Prostate tissues were
obtained from the radical prostatectomy series and
the Rapid Autopsy Program, both of which are part
of the University of Michigan Prostate Cancer Special-
ized Program of Research Excellence (S.P.O.R.E.) Tis-
sue Core. All samples were collected with informed
consent of the patients and prior institutional review
board approval. For all tissue samples and cell lines,
total RNA was isolated with Trizol reagent (Invitro-
gen) according to the manufacturer’s instructions.
Various doses of dutasteride were used to test the
proliferative response. Cells were washed and sup-
plemented with phenol red-free medium containing
5% charcoal dextran-treated FBS (Cambrex Corp.,
East Rutherford, NJ) for 48 hr prior to androgen treat-
ment. For fusion gene expression studies, cells were
pre-incubated with dutasteride for 2 hr and then
treated with either T or DHT or dutasteride to test the
effect of dutasteride on the conversion of T to DHT.
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Cell ProliferationAssay
Equal numbers of VCaP cells were plated and
grown to 70% confluence before treatment with vary-
ing doses of dutasteride and/or T and DHT. Cells
were trypsinized 48-hr post-treatment and triplicate
cell counts were obtained at appropriate time points
using a Coulter counter (Beckman Coulter, Fullerton,
CA) as described previously [4].
BoydenChamberMatrigelCell InvasionAssay
Boyden chamber invasion assays were performed
using VCaP cells treated with R1881, T, DHT, or
dutasteride, either alone or in combination. Cells
were seeded onto the basement membrane matrix
(Millipore, Bedford, MA) present on the insert of a
24-well culture plate. FBS was added to the lower
chamber as a chemoattractant. After 48 hr the non-
invading cells and EC matrix were gently removed
with a cotton swab. Invasive cells located on the outer
side of the chamber were stained with crystal violet
and air-dried. For colorimetric assays, the inserts
were destained with 150 ml of 10% acetic acid and the
absorbance was measured at 560 nm by a spectropho-
tometer (GE Healthcare, Piscataway, NJ) as described
previously [19].
QuantitativeReal-TimePCR
Quantitative PCR was performed using Power
SYBR Green Mastermix (Applied Biosystems, Foster
City, CA) on an Applied Biosystems 7300 Real Time
PCR system as previously described [1,20]. All oligo-
nucleotide primers were synthesized by Integrated
DNA Technologies (IDT, Coralville, IA). All reactions
were performed in duplicate unless otherwise indicat-
ed. HMBS was used as control. The sequences of the
primers for the three SRD5A isoforms, fusion tran-
script TMPRSS2–ERG and GAPDH are listed below:
SRD5A1
Forward primer: 50-CCTGTTTGTTCTTTGTTGATT-
GAA-30
Reverse primer: 50-CCAGATGAGATGATAAGGCA-
AAG-30
SRD5A2
Forward primer: 50-ATCTGAACATACAGAGCCCA-
CAT-30
Reverse primer: 50-ATCCTCAGACCTTTCAAGTTT-
CC-30
SRD5A3
Forward primer: 50-TTTAATCAGGCCCTGTCTGC-30
Reverse primer: 50-GGGGTATAGAAATGGAATGG-
AGA-30
TMPRSS2–ERG
Forward primer: 50-TAGGCGCGAGCTAAGCAGG-
AG-30
Reverse primer: 50-GTAGGCACACTCAAACAACG-
ACTGG-30
GAPDH
Forward primer: 50-TGCACCACCAACTGCTTAGC-30
Reverse primer: 50-GGCATGGACTGTGGTCATGAG-30
ImmunoblotAnalysis
Control and treated VCaP cells were lysed with
NP-40 lysis buffer containing 50 mM Tris–HCl, pH
7.4, 1% Nonidet P-40 (Sigma, St. Louis, MO) and com-
plete protease inhibitor cocktail (Roche, IN). Ten
micrograms of protein extract were prepared in SDS
sample buffer and electrophoresed onto a 4–12%
NUPAGE Bis-Tris gel (Life Technologies, Grand Is-
land, NY) under reducing conditions and transferred
onto nitrocellulose membranes (GE Healthcare). The
membrane was incubated for 1 hr in blocking buffer
[Tris-buffered saline with 0.1% Tween (TBS-T) and
5% non-fat dry milk] followed by the addition of
ERG1 rabbit polyclonal antibody (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA) and PSA rabbit poly-
clonal antibody (Dako, Dako Denmark A/S 1:10,000)
antibody and incubated overnight at 48C. After wash-
ing three times with TBS-T buffer, the membrane was
incubated with horseradish peroxidase-linked donkey
anti-rabbit IgG antibody (GE Healthcare) at a 1:5,000
dilution for 1 hr at room temperature. The signals
were visualized with the enhanced chemilumines-
cence detection system (GE Healthcare) and autoradi-
ography. Rabbit anti-actin antibody (Sigma) was
applied at 1:30,000 and served as loading control.
VCaP-LuciferaseXenograftModel
Two million prostate cancer VCaP cells overex-
pressing luciferase (VCaP-Luc) were resuspended in
100 ml of saline with 50% Matrigel (BD Biosciences,
Mountain View, CA) and were subcutaneously
implanted into the left flank region of the 4-week-old
male Balb C nu/nu mice. Three weeks later mice
(n ¼ 40) with palpable tumors were randomized into
four groups, and were treated with dutasteride
(0.1 mg/kg body weight), bicalutamide (12 mg/kg
body weight), or a combination of both intraperitone-
ally daily five times a week. Growth in tumor volume
was recorded weekly using digital calipers, and tu-
mor volumes were calculated using the formula (p/6;
L  W2), where L ¼ length of tumor and W ¼ width.
In vivo bioluminescent imaging was performed week-
ly using an IVIS-200 imaging system (Caliper Life
Sciences, Hopkinton, MA). Fifteen minutes prior to
imaging, mice were given 150 mg/kg of luciferin by
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intraperitoneal injection. All images were collected
and analyzed by using Living Image software (Xeno-
gen Corporation). All procedures involving mice
were approved by the University Committee on Use
and Care of Animals (UCUCA) at the University of
Michigan and conform to all relevant regulatory
standards.
StatisticalAnalyses
All data are presented as mean  SEM, and signifi-
cance was determined by two-tailed Student’s t-test.
RESULTS
Expressionof SRD5AIsoformsinProstate
Cell Lines andTumorTissues
Quantitative RT-PCR was performed using RNA
from androgen responsive prostate derived cell lines
LNCaP and VCaP as well as normal and prostate
tumor tissues to evaluate the expression of SRD5A1,
SRD5A2, and SRD5A3. SRD5A3 was highly expressed
in both LNCaP (ETV1 rearrangement positive) and
VCaP (TMPRSS2–ERG positive) cell lines, whereas
SRD5A1 expression was modestly elevated in VCaP
cells only (Fig. 1A). Expression of SRD5A2 was very
low in both cell lines (Fig. 1A).
Analysis of benign prostate and prostate cancer tis-
sue samples revealed unique expression patterns of
the three 5a-reductase enzymes. While the expression
level of SRD5A1 and SRD5A3 increased during pros-
tate cancer progression (from benign to metastatic
disease), there was a concurrent decrease in SRD5A2
(Fig. 1B). Consistent with the cell line studies,
SRD5A3 expression was higher than SRD5A1 across
all stages of the prostate cancer development
(Fig. 1B).
To evaluate the effect of dutasteride on VCaP cell
proliferation and viability, the cells with varying
doses of dutasteride for 48 hr. Upon treatment the
VCaP cells underwent morphological changes exhib-
iting spindle like phenotype (Fig. 2A, inset). No sig-
nificant change in the cell number at lower doses of
dutasteride treatment were observed, however there
was a significant decrease in cell proliferation at
10 mM (P ¼ 0.03) and a marked decrease at 50 mM
(P ¼ 0.002; Fig. 2A). These results suggest a growth
inhibitory effect of dutasteride on the TMPRSS2–ERG
fusion positive VCaP cell line.
We next tested the effect of dutasteride on cell in-
vasion using Matrigel-coated Boyden chamber inva-
sion assay. VCaP cells were treated with dutasteride
alone, or in combination with T and DHT. As shown
in Figure 2B, both DHT and T treatment resulted in
a marked increase in cell invasion (P ¼ 0.007 and
P ¼ 0.02, respectively) and treatment with the syn-
thetic androgen, R1881, displayed the highest level
(>5-fold) of invasive phenotype (Fig. 2B; P ¼ 0.001).
Importantly, dutasteride treatment significantly re-
duced the T- or DHT-mediated cell invasion
(Fig. 2B; P ¼ 0.03 and P ¼ 0.02, respectively). These
results clearly demonstrate the effectiveness of dutas-
teride in attenuating the invasive potential of ERG-
positive prostate cancer cells.
Dutasteride InhibitstheExpressionof
TMPRSS2^ERGLevelin FusionPositiveVCaPCells
To evaluate the effect of dutasteride on TMPRSS2–
ERG expression, VCaP cells were treated with dutas-
teride, T or DHT alone, or pre-incubated with
dutasteride before treating with T or DHT. Quantita-
tive real-time PCR analysis showed significant reduc-
tion in the TMPRSS2–ERG fusion transcript with
50 mM of dutasteride treatment alone compared to
vehicle-treated serum starved VCaP cells (Fig. 3A).
We also observed a modest reduction in TMPRSS2–
ERG fusion transcript in the VCaP cells pre-treated
with dutasteride followed by T or DHT treatment
compared to T or DHT treatment alone (Fig. 3A).
Although dutasteride could further inhibit the basal
level expression of ERG in androgen-depleted medi-
um, we did not observe a concurrent reduction in the
ERG protein in the cells pre-treated with dutasteride
followed by T or DHT treatment (Fig. 3B). Treatment
with T or DHT alone resulted in the induction of
TMPRSS2–ERG fusion transcript as well as PSA and
Fig. 1. Expression of 5a -reductases in prostate cancer cell
lines and tissue samples. A: Quantitative SYBR green RT-PCR of
5a -reductase isoforms SRD5A1, SRD5A2, and SRD5A3 in ETS
fusion-positive cell lines LNCaP and VCaP. B: Box plot depicting
expression levels of three isoforms of 5a -reductase in benign
prostate tissue, primary prostate cancer and metastatic prostate
cancer samples (n ¼ 8 foreachclass).
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ERG proteins as anticipated (Fig. 3A,B). These find-
ings suggest that the inhibition of T conversion to
DHT was not effective in blocking the fusion gene
expression. In addition, we observed a significant in-
crease in T converting enzymes SRD5A1 and SRD5A2
upon dutasteride treatment (Fig. 3C), suggesting a
possible effect of T itself on the induction of fusion
gene as well as the possible residual conversion to
DHT.
DutasterideinCombinationWithBicalutamide
ReducesTumorGrowthinTMPRSS2^ERG
PositiveXenograftModel
Next, we investigated the potential of dutasteride
to inhibit tumor growth using an in vivo VCaP xeno-
graft model system. We administered dutasteride
alone or in combination with the anti-androgen,
bicalutamide, to immunodeficient mice that were
implanted with VCaP-luc cells subcutaneously. Three
weeks later mice with pre-established tumors were
randomized into four groups and were treated with
dutasteride (0.1 mg/kg body weight), bicalutamide
(12 mg/kg body weight), or a combination of both
daily five times a week. Dutasteride alone was unable
to demonstrate any significant anti-tumor effect, less
than 20% reduction in tumor burden was recorded
in this group. Likewise, bicalutamide treatment dem-
onstrated about 30% reduction in tumor burden
when administered alone (P ¼ 0.007 and P ¼ 0.01 at
weeks 6 and 7, respectively). However, a combination
of dutasteride and bicalutamide resulted in a signifi-
cant reduction in tumor growth (55% reduction)
compared to untreated (Fig. 4A; P ¼ 0.0001 and
P ¼ 0.001 at weeks 6 and 7, respectively). Similar
results were obtained using bioluminescence imaging
(Fig. 4B) where a significant decrease in photon flux
was recorded in the group treated with dutasteride
and bicalutamide combination compared to single
drug treatment group. These results suggest that the
inhibition of the DHT converting enzyme by dutaster-
ide, in combination with anti-androgen, could lead to
a marked reduction in tumor growth.
DISCUSSION
The prostate cancer specific TMPRSS2–ERG fusion
gene induces the overexpression of the oncogenic pro-
tein, ERG that facilitates tumor progression and
serves as a potential therapeutic target. The direct in-
hibition of transcription factors such as ERG is diffi-
cult because of the lack of an enzymatic activity and
inaccessibility due to nuclear localization. However,
blocking the function of regulatory proteins like AR
may be more feasible as expression of the fusion gene
is activated by AR-androgen axis. Increasing evidence
suggest that enhanced intratumoral androgen synthe-
sis may be one cause of resistance to androgen depri-
vation therapy. A recent study indicated that
men who underwent transperineal three-dimensional
mapping (TP-3DM) biopsy of the prostate and re-
ceived dutasteride treatment for at least 3 months be-
fore biopsy showed 24% decrease in the upstaging
and/or upgrading of prostate cancer compared to the
control group that did not receive dutasteride [21],
demonstrating a potential role for dutasteride in ter-
tiary chemoprevention. Another large-scale clinical
trial showed that dutasteride reduced the risk of
Fig. 2. DutasterideinhibitsVCaPcellproliferationandinvasion.A: CellproliferationassayusingVCaPcells treatedwithvaryingconcentra-
tions of dutasteride.Photomicrograph ofuntreated and 50 mMdutasteride treatedcells are shownin the inset.B:BoydenChamberMatrigel
invasionassayshowinginvasivepotentialofVCaPcellsunderdifferentexperimentalconditions asindicated.
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incident prostate cancer detected on biopsy and im-
proved the outcomes related to benign prostatic hy-
perplasia [22]. Further, combining dutasteride with a
CYP17A1 inhibitor ketoconazole in CRPC had benefi-
cial effects resulting in remarkable prolongation of
progression time compared to single agent regimen
[23]. However, the mechanism of dutasteride-mediat-
ed chemoprevention is not clearly understood.
Here, we analyzed the expression of three isoforms
of 5a-reductases in benign prostate and prostate can-
cer tissue samples and confirmed the increased
expression of SRD5A1 and SRD5A3 in metastatic
samples compared to benign and primary prostate
cancer. A recent study indicated that SRD5A1 utilizes
androstenedione as substrate in CRPC and converts
it to DHT via an intermediate 5a-androstanedione
Fig. 3. Effect of dutasteride on PSA and ERG expression
in VCaP cells. A: Quantitative SYBR green RT-PCR showing
TMPRSS2^ERG fusion transcript expression in VCaP cells treated
withethanol,DHT,orT aloneand/or in thepresence ofdutasteride.
B: Experimental groups same as in (A), except representative
immunoblots are shown for the ERG and PSA protein expression.
C: Quantitative SYBR green RT-PCR showing SRD5A1 and
SRD5A3 transcripts expression inVCaP cells treatedwith ethanol,
DHT,orT aloneand/or in thepresenceofdutasterideasindicated.
Fig. 4. Effectofdutasterideandbicalutamidecombination thera-
py on VCaP tumor growth. A: Line graph showing mean tumor
volume recorded from the immunodeficientmicebearing subcuta-
neous VCaP-Luc xenografts. B: Experimental groups same as in
(A), except bar graph showing mean photon flux. Representative
bioluminescent images show mice bearing VCaP-Luc tumors at
week6.
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[15]. Therefore, we investigated the possibility of
dutasteride-dependent inhibition of AR activity by
blocking the conversion of T to DHT by 5a-reductase.
In addition, we also tested a combined therapy using
the anti-androgen, bicalutamide, and the 5a-reductase
inhibitor, dutasteride.
Results of the current study demonstrate that
dutasteride is effective in reducing the expression of
the fusion gene TMPRSS2–ERG transcript even in the
presence of T, but not at the protein level. Dutasteride
inhibits cell proliferation and blocks the invasiveness
of the fusion-positive VCaP cells in the presence of
T or DHT. In addition, treatment with dutasteride in
combination with anti-androgen reduces tumor bur-
den significantly, demonstrating an additive tumor
suppressive effect in the TMPRSS2–ERG fusion driv-
en xenograft model. The mechanism underlying this
additive effect is unclear and warrants further investi-
gation. Our data suggest that dutasteride is only
targeting one arm of the androgen pathway; hence,
combining with other anti-androgens such as bicalu-
tamide could be more beneficial compared to single
agent treatment. Moreover, the recent identification
of two diarylthiohydantoin compounds, RD162 and
MDV3100, that bind to the AR with greater relative
affinity than the bicalutamide could prove even more
beneficial in combination therapy than the first gener-
ation anti-androgens [24].
In summary, our study provides a rationale for
utilizing dutasteride, which has been extensively
used for the symptomatic benign prostatic hyperpla-
sia treatment, in combination with anti-androgens to
treat TMPRSS2-ETS rearrangement-positive prostate
cancer patients.
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